Rituximab Ups Survival in CLL, University of Cologne Study

MPT -- Adding the monoclonal antibody rituximab (Rituxan) to initial chemotherapy significantly improved progression-free and overall survival in patients with chronic lymphocytic leukemia (CLL), a prospective study found.